Schedule of Summarizes Information About Stock Options (Details) - USD ($) $ / shares in Units, $ in Thousands		9 Months Ended		12 Months Ended
		Sep. 30, 2022		Dec. 31, 2021
2014 Equity Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of Stock Options Outstanding, Beginning Balance		8,720,198
Weighted Average Exercise Price, Beginning Balance		$ 3.39
Remaining Contractual Term (Years)		6 years 9 months 18 days
Intrinsic Value Outstanding, Beginning Balance	[1]	$ 3,516
Number of Stock Options, Granted	[2]	4,734,350
Weighted Average Exercise Price, Granted	[2]	$ 1.54
Number of Stock Option, Exercised		(299,999)
Weighted Average Exercise Price, Exercised		$ 1.01
Number of Stock Option, Forfeited		(1,542,978)
Weighted Average Exercise Price, Forfeited		$ 3.13
Number of Stock Options Outstanding, Ending Balance		11,611,571	[3]	8,720,198
Weighted Average Exercise Price, Ending Balance		$ 2.73	[3]	$ 3.39
Remaining Contractual Term (Years)	[3]	7 years 8 months 12 days
Intrinsic Value Outstanding, Ending Balance	[1]		[3]	$ 3,516
Number of Stock Options Vested and exercisable stock options		6,623,157
Weighted Average Exercise Price, Vested and exercisable stock options		$ 3.01
Remaining Contractual Term (Years), Vested and exercisable stock options		6 years 6 months
Intrinsic Value Exercisable, Ending Balance	[1]
2018 Equity Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of Stock Options Outstanding, Beginning Balance		1,419,242
Weighted Average Exercise Price, Beginning Balance		$ 0.73
Remaining Contractual Term (Years)		7 years
Intrinsic Value Outstanding, Beginning Balance	[4]	$ 6,665
Number of Stock Options, Granted		2,320,000
Weighted Average Exercise Price, Granted		$ 3.71
Number of Stock Option, Exercised		(964,717)
Weighted Average Exercise Price, Exercised		$ 0.72
Number of Stock Option, Forfeited		(141,436)
Weighted Average Exercise Price, Forfeited		$ 4.33
Number of Stock Options Outstanding, Ending Balance		2,633,089		1,419,242
Weighted Average Exercise Price, Ending Balance		$ 3.17		$ 0.73
Remaining Contractual Term (Years)		8 years 7 months 6 days
Intrinsic Value Outstanding, Ending Balance	[4]	$ 499	[5]	$ 6,665
Number of Stock Options Vested and exercisable stock options		960,364
Weighted Average Exercise Price, Vested and exercisable stock options		$ 2.33
Remaining Contractual Term (Years), Vested and exercisable stock options		7 years 2 months 12 days
Intrinsic Value Exercisable, Ending Balance	[4]	$ 499
2018 Equity Plan [Member] | Parent Company [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of Stock Options, Granted		500,854		500,854

[1] The intrinsic value is computed as the difference between the quoted price of the PAVmed Inc. common stock on each of September 30, 2022 and December 31, 2021 and the exercise price of the underlying PAVmed Inc. stock options, to the extent such quoted price is greater than the exercise price.

[2] Stock options granted under the PAVmed Inc. 2014 Equity Plan and those granted outside such plan generally vest ratably over twelve quarters, with the vesting commencing with the grant date quarter-end, and have a ten-year contractual term from date-of-grant.

[3] The outstanding stock options presented in the table above, are inclusive of 500,854 stock options granted outside the PAVmed Inc. 2014 Equity Plan, as of September 30, 2022 and December 31, 2021.

[4] The intrinsic value is computed as the difference between the quoted price of the Lucid Diagnostics Inc. common stock on each of September 30, 2022 and December 31, 2021 and the exercise price of the underlying Lucid Diagnostics Inc. stock options, to the extent such quoted price is greater than the exercise price.

[5] The outstanding stock options presented in the table above, are inclusive of 423,300 stock options granted outside the Lucid Diagnostics Inc. 2018 Equity Plan, as of September 30, 2022 and December 31, 2021.